Correlation Between Eupraxia Pharmaceuticals and Medexus Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and Medexus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and Medexus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eupraxia Pharmaceuticals and Medexus Pharmaceuticals, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and Medexus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of Medexus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and Medexus Pharmaceuticals.

Diversification Opportunities for Eupraxia Pharmaceuticals and Medexus Pharmaceuticals

0.43
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Eupraxia and Medexus is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals and Medexus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medexus Pharmaceuticals and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals are associated (or correlated) with Medexus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medexus Pharmaceuticals has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and Medexus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Eupraxia Pharmaceuticals and Medexus Pharmaceuticals

Assuming the 90 days trading horizon Eupraxia Pharmaceuticals is expected to generate 0.92 times more return on investment than Medexus Pharmaceuticals. However, Eupraxia Pharmaceuticals is 1.08 times less risky than Medexus Pharmaceuticals. It trades about 0.13 of its potential returns per unit of risk. Medexus Pharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest  549.00  in Eupraxia Pharmaceuticals on April 24, 2025 and sell it today you would earn a total of  138.00  from holding Eupraxia Pharmaceuticals or generate 25.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy98.41%
ValuesDaily Returns

Eupraxia Pharmaceuticals  vs.  Medexus Pharmaceuticals

 Performance 
       Timeline  
Eupraxia Pharmaceuticals 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Eupraxia Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.
Medexus Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Over the last 90 days Medexus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Medexus Pharmaceuticals is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Eupraxia Pharmaceuticals and Medexus Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eupraxia Pharmaceuticals and Medexus Pharmaceuticals

The main advantage of trading using opposite Eupraxia Pharmaceuticals and Medexus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, Medexus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will offset losses from the drop in Medexus Pharmaceuticals' long position.
The idea behind Eupraxia Pharmaceuticals and Medexus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities